1. Measured by its ability to inhibit TGF-beta 1 activity on TF‑1 human erythroleukemic cells. The ED50 for this effect is 0.37ng/ml. (Regularly tested) 2. Immobilized Human TGFBR2-Fc at 2μg/ml (100 μl/well)can bind Biotinylated Human TGF-beta 3-Avi . The ED50 of Biotinylated Human TGF-beta 3-Avi is 2.05 ng/ml. (Regularly tested)

Transforming growth factor beta (TGFβ) is a multifunctional cytokine that regulates cell growth, differentiation, adhesion, migration and death dependent on cell type, developmental stage, or tissue conditions. There are three isoforms of TGFβ (TGFβ-1, -2 and -3). TGF-beta-3 is released from LAP by integrins: integrin-binding results in distortion of the LAP chain and subsequent release of the active TGF-beta-3. TGF-beta 3 binds with high affinity to TGF-beta RII, a type II serine/threonine kinase receptor. This receptor then phosphorylates and activates type I serine/threonine kinase receptors, TGF-beta RI or ALK-1, to modulate transcription through Smad phosphorylation.

Greater than 95% as determined by reducing SDS-PAGE. (QC verified)